Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Descending) Status
51285-0366-01 51285-0366 Methotrexate Trexall 5.0 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 3, 2001 In Use
51285-0367-01 51285-0367 Methotrexate Trexall 7.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 3, 2001 In Use
51285-0368-01 51285-0368 Methotrexate Trexall 10.0 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 3, 2001 In Use
51285-0369-01 51285-0369 Methotrexate Trexall 15.0 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 3, 2001 In Use
51672-4118-02 51672-4118 Fluorouracil Fluorouracil 50.0 mg/g Chemotherapy Antimetabolite Pyrimidine Analog Topical March 17, 2017 In Use
51672-4118-05 51672-4118 Fluorouracil Fluorouracil 50.0 mg/g Chemotherapy Antimetabolite Pyrimidine Analog Topical March 17, 2017 In Use
51672-4118-06 51672-4118 Fluorouracil Fluorouracil 50.0 mg/g Chemotherapy Antimetabolite Pyrimidine Analog Topical March 17, 2017 In Use
50242-0130-01 50242-0130 ALECTINIB HYDROCHLORIDE Alecensa 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Dec. 11, 2015 In Use
50242-0130-86 50242-0130 ALECTINIB HYDROCHLORIDE Alecensa 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Oct. 10, 2017 In Use
54569-1818-09 54569-1818 METHOTREXATE, Methotrexate sodium Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Dec. 7, 1953 In Use
54868-5474-00 54868-5474 Erlotinib Hydrochloride Tarceva 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 21, 2005 In Use
55111-0556-10 55111-0556 Decitabine Decitabine 50.0 mg/10mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 11, 2013 In Use
57962-0070-28 57962-0070 Ibrutinib IMBRUVICA 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Dec. 20, 2017 In Use
57962-0140-09 57962-0140 Ibrutinib Imbruvica 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Nov. 13, 2013 In Use
57962-0140-12 57962-0140 Ibrutinib Imbruvica 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Nov. 13, 2013 In Use
57962-0280-28 57962-0280 Ibrutinib IMBRUVICA 280.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 16, 2018 In Use
57962-0420-28 57962-0420 Ibrutinib IMBRUVICA 420.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 16, 2018 In Use
57962-0420-71 57962-0420 Ibrutinib IMBRUVICA 420.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 6, 2019 In Use
60687-0149-94 60687-0149 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 7, 2016 In Use
61703-0309-06 61703-0309 Vincristine Sulfate Vincristine Sulfate 1.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Jan. 1, 1996 In Use
61703-0309-16 61703-0309 Vincristine Sulfate Vincristine Sulfate 1.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Jan. 1, 1996 In Use
61703-0309-25 61703-0309 Vincristine Sulfate Vincristine Sulfate 1.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Nov. 27, 2013 In Use
61703-0309-26 61703-0309 Vincristine Sulfate Vincristine Sulfate 1.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Feb. 19, 2014 In Use
61703-0323-22 61703-0323 Bleomycin Bleomycin 30.0 [USP'U]/1 Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intramuscular, Intrapleural, Intravenous, Subcutaneous April 10, 2000 In Use
61703-0332-18 61703-0332 Bleomycin Bleomycin 15.0 [USP'U]/1 Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intramuscular, Intrapleural, Intravenous, Subcutaneous April 11, 2000 In Use
61703-0339-18 61703-0339 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 14, 2004 In Use
61703-0339-22 61703-0339 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 14, 2004 In Use
61703-0339-50 61703-0339 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 14, 2004 In Use
61703-0339-56 61703-0339 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Nov. 23, 2004 In Use
61703-0343-18 61703-0343 Mitoxantrone Mitoxantrone 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous April 11, 2006 In Use
61703-0343-65 61703-0343 Mitoxantrone Mitoxantrone 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous April 11, 2006 In Use
61703-0343-66 61703-0343 Mitoxantrone Mitoxantrone 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous April 11, 2006 In Use
61703-0349-09 61703-0349 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 27, 2008 In Use
61703-0349-16 61703-0349 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 27, 2008 In Use
61703-0349-36 61703-0349 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 27, 2008 In Use
61703-0363-18 61703-0363 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug. 10, 2009 In Use
61703-0363-22 61703-0363 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug. 10, 2009 In Use
62484-0020-01 62484-0020 Purixan Purixan 20.0 mg/mL Chemotherapy Antimetabolite Purine Analog Oral April 28, 2014 In Use
62484-0020-02 62484-0020 Purixan Purixan 20.0 mg/mL Chemotherapy Antimetabolite Purine Analog Oral April 28, 2014 In Use
62856-0177-08 62856-0177 Carmustine implant/ polifeprosan 20, polifeprosan 20 with carmustine implant Gliadel 7.7 mg/1 Chemotherapy Alkylating Agent Nitrosourea Intracavitary In Use
63323-0117-10 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 2, 2017 In Use
63323-0117-18 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 12, 2000 In Use
63323-0117-19 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 12, 2000 In Use
63323-0117-20 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 2, 2017 In Use
63323-0117-28 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 12, 2000 In Use
63323-0117-51 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 12, 2000 In Use
63323-0117-58 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 12, 2000 In Use
63323-0117-59 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 12, 2000 In Use
63323-0117-61 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 12, 2000 In Use
63323-0117-68 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 12, 2000 In Use

Found 10,000 results in 6 millisecondsExport these results